Replies to post #136126 on Biotech Values

[DewDiligence]

PFE’s new 2012 non-GAAP EPS guidance after adjusting for the divestiture of the Nutrition business (which is now accounted for as a discontinued operation) is $2.14-2.24:

http://finance.yahoo.com/news/Pfizer-Reports-First-Quarter-bwtmp-2104763031.html?x=0&.v=1&c=1

The old guidance (including the Nutrition business) was $2.20-2.30.

The rest of the commentary in #msg-71524448 re PFE’s valuation and status as a beneficiary of The Global Demographic Tailwind is unchanged.